HeartBeam (NASDAQ: BEAT) has announced the launch of a pilot study focused on testing its proprietary on-demand 12-lead ECG patch for detecting coronary artery disease and ischemia—a condition characterized by inadequate blood flow and oxygen supply to tissue. The study marks a significant milestone in the development of the HeartBeam patch, which has the potential to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (MCT) markets.
Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of deaths each year and often progressing silently until a major cardiac event occurs. As healthcare providers search for faster and more accessible ways to identify high-risk patients earlier, HeartBeam's technology aims to fill a critical gap. According to the company, ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time. The HeartBeam patch is designed to change that by enabling on-demand generation of a 12-lead ECG, which is the gold standard for diagnosing cardiac ischemia.
HeartBeam CEO Robert Eno stated, "Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time. The HeartBeam patch is designed to change that. A device capable of generating an on-demand 12-lead ECG could provide clinicians with actionable data to identify patients at risk earlier." The pilot study will evaluate the patch's ability to detect coronary artery disease and ischemia, potentially enabling earlier intervention and improved outcomes for patients.
The launch of this study is particularly timely given the increasing prevalence of cardiovascular risk factors and an aging population. If successful, the HeartBeam patch could offer a non-invasive, convenient solution for continuous monitoring outside of clinical settings. This would represent a significant advancement over current patch monitors, which typically provide only single-lead or limited ECG data and cannot reliably detect ischemia.
HeartBeam's technology is based on a proprietary algorithm that reconstructs a 12-lead ECG from signals captured by a small, wearable patch. The patch is designed for long-term use and allows patients to record an ECG on-demand when symptoms occur, providing clinicians with critical data that might otherwise be missed. The company believes this could reduce the need for more invasive diagnostic procedures and lower healthcare costs.
The study is expected to enroll participants and generate data that will support further development and regulatory submissions. For more information about HeartBeam and its technology, visit the company's newsroom at https://ibn.fm/BEAT. The full terms of use and disclaimers are available on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
